Unknown

Dataset Information

0

Plasma endostatin predicts kidney outcomes in patients with type 2 diabetes.


ABSTRACT: Novel biomarkers are needed to predict kidney function decline in patients with type 2 diabetes, especially those with preserved glomerular filtration rate (GFR). There are limited data on the association of markers of endothelial dysfunction with longitudinal GFR decline. We used banked specimens from a nested case-control study in the Action to Control Cardiovascular Disease (ACCORD) trial (n=187 cases: 187 controls) and from a diverse contemporary cohort of type 2 diabetic patients from the Mount Sinai BioMe Biobank (n=871) to assess the association of plasma endostatin and kidney outcomes. We measured plasma endostatin at enrollment and examined its association with a composite kidney outcome of sustained 40% decline in estimated GFR or end-stage renal disease. Baseline plasma endostatin levels were higher in participants with the composite outcome. Each log2 increment in plasma endostatin was associated with approximately 2.5-fold higher risk of the kidney outcome (adjusted odds ratio [OR] 2.5; 95% confidence interval [CI] 1.5-4.3 in ACCORD and adjusted hazard ratio [HR] 2.6; 95% CI 1.8-3.8 in BioMe). Participants in the highest vs. lowest quartile of plasma endostatin had approximately four-fold higher risk for the kidney outcome (adjusted OR 3.6; 95% CI 1.8-7.3 in ACCORD and adjusted HR 4.4; 95% CI 2.3-8.5 in BioMe). The AUC for the kidney outcome improved from 0.74 to 0.77 in BioMe with the addition of endostatin to a base clinical model. Plasma endostatin was strongly associated with kidney outcomes in type 2 diabetics with preserved eGFR and improved risk discrimination over traditional predictors.

SUBMITTER: Chauhan K 

PROVIDER: S-EPMC6342645 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Plasma endostatin predicts kidney outcomes in patients with type 2 diabetes.

Chauhan Kinsuk K   Verghese Divya Anna DA   Rao Veena V   Chan Lili L   Parikh Chirag R CR   Coca Steven G SG   Nadkarni Girish N GN  

Kidney international 20181224 2


Novel biomarkers are needed to predict kidney function decline in patients with type 2 diabetes, especially those with preserved glomerular filtration rate (GFR). There are limited data on the association of markers of endothelial dysfunction with longitudinal GFR decline. We used banked specimens from a nested case-control study in the Action to Control Cardiovascular Disease (ACCORD) trial (n=187 cases: 187 controls) and from a diverse contemporary cohort of type 2 diabetic patients from the M  ...[more]

Similar Datasets

| S-EPMC3816878 | biostudies-other
| S-EPMC7677996 | biostudies-literature
| S-EPMC7864612 | biostudies-literature
| S-EPMC8247517 | biostudies-literature
| S-EPMC9209993 | biostudies-literature
| S-EPMC4212578 | biostudies-literature
| S-EPMC8830527 | biostudies-literature
| S-EPMC8362174 | biostudies-literature
| S-EPMC9357198 | biostudies-literature
| S-EPMC9862371 | biostudies-literature